DOCUMENTS

99

 

NOTICES

156

 

 

MOTS CLES

Acute Myeloid Leukaemia AML Systematic review Glucocorticoids Amyloidosis Ethics Alcohol Axial spondyloarthritis ASDAS Antibiotic resistance Ankylosing spondylitis Vigibase® Apremilast Azathioprine Alitretinoin Management Biologic Beta-lactam antibiotics Spondyloarthritis Anxiety Sacroiliitis Biologic therapy Pharmacovigilance Epidemiology Pharmaco-Épidémiologie Drug survival Psoriatic arthritis Biomarkers Angiotensin-converting enzyme inhibitors Meta-Analysis Biosimilar Pharmaceuticals Ustekinumab Immune-related adverse events Primary adrenal insufficiency COVID-19 Antibiotics Aging Cardio-oncology Auto-Diagnostic Autoimmunity Auto-immune hepatitis BTK protein Biologic drug Anticancer drugs Stability Méta-Analyse Immune checkpoint inhibitors Bacterial Sipuleucel-T Arrhythmia Cardiomyopathy Bacterial rhinosinusitis Dermatology Graft-versus-host disease Endocrine toxicity Treatment Angiotensin receptor blockers Adverse side effects Biomédicaments Accelerometer Cohort studies Prostate cancer Pregnancy ArtThese Drug reaction Apre-milast Arthritis Adalimumab Quality of life Antibiotic misuse Cardiotoxicity Anti-Bacterial Agents Antimicrobial resistance Immunotherapy Biological Therapy Access to care Ankylosing Intensive care Autoimmune diseases Anxiété Anti-HCV Direct Acting Antivirals DAA Biological therapy Antimicrobiens Network meta-analysis Etanercept Cancer Pharmacoepidemiology Antimicrobials Addiction Antimicrobial Stewardship Spondylitis Albinism Placebo Atrial fibrillation Psoriasis Anti-TNF Abus d'antibiotiques Infliximab Adolescent Atopic dermatitis Biologics

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS